🔎︎
A qualitative study published in JAMA Network Open offers managed care decision-makers a rare look at how patients themselves weigh the trade-off at the center of many oncology coverage debates: speed of access versus the certainty that a drug actually works. Researchers led by Robin Forrest interviewed 30 women with breast cancer across 17 states about the US Food and Drug Administration's Accelerated Approval pathway, which clears drugs for serious conditions on surrogate measures only reasonably likely to predict benefit, leaving confirmation to later trials.
The central finding is one that payers will recognize. Participants accepted greater uncertainty about clinical benefit in only two situations: when no alternative treatment existed, or when a new therapy promised a transformative gain in survival or quality of life. When effective options were already available, or when an incoming drug looked like a marginal addition to a crowded class, they wanted firmer evidence before approval, even if that meant waiting. They consistently named overall survival and preserved daily functioning as the outcomes that mattered most, and they weighed the real costs of added side effects and treatment burden against uncertain upside.
The authors note that most breast cancer drugs granted accelerated approval over the past two decades targeted indications that already had treatment options, and that gains in survival or quality of life have been uncommon and modest when present. The conditions under which patients find uncertainty acceptable are not the conditions under which many of these drugs are added to the formulary.
For plans, the study lends patient voice to evidence-based coverage. Its findings support tying access for lower-certainty drugs to confirmatory data, prioritizing therapies that fill genuine gaps, and using clinical-benefit measures to separate transformative entrants from fast followers. Several participants viewed broader clinical trial access, rather than faster blanket approval, as the better route to early access, a view that aligns with coverage-with-evidence approaches. The authors conclude that accelerated approval may be most appropriate for drugs that address real treatment gaps or offer meaningful improvement over existing care.
